Physician profile
Satbir Singh
NPI 1477560613
$9,935.93
in general payments reported to CMS, 2019-2025
8 companies · $325 in 2025
The $325 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.00 · 2020: $12.76 · 2022: $144 · 2023: $28.25 · 2024: $9,351 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $9,400 · Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $9,400.33 |
| Food and Beverage | $303.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $9,400.33 | 2024-2025 | |
| Antares Pharma, INC. | $216.02 | 2024-2025 | Xyosted |
| Astellas Pharma US INC | $169.32 | 2019-2022 | |
| Tolmar, INC. | $87.52 | 2023-2024 | |
| Boston Scientific Corporation | $35.54 | 2019-2022 | |
| Pfizer INC. | $14.63 | 2019 | |
| Neotract INC. | $12.57 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$18,040.64 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satbir Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.